Within the US, breast cancer claims over 40,000 lives annually, placing it as the second highest cancer-related mortality causing disease. Fortunately, advances in screening and breast cancer management combined with earlier diagnoses has led to significant declines in breast cancer related deaths in the older population, as reported by the ACS. Approximately 80% of breast cancer diagnoses can be attributed to ductal carcinoma, which originates in the milk ducts before spreading to the surrounding breast tissue. Preclinical research, where transfection is a staple technique, continues to provide novel advances for breast cancer treatment. The HCC1937 cell line, in 1996, was established from the primary mammary gland ductal tumor classified as TNM Stage2B/grade3. HCC1937 cells have been used in many breast cancer studies and could be useful for investigating possible inheritable genetic cancer-causing mutations. Altogen Biosystems has developed a polymer-based HCC1937 specific transfection kit, which can be found at:
[ Ссылка ]

свернуть